drugset
drugset / Trial / NCT06712810

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810 ↗

Phase 1 Recruiting 46 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.

Timeline

Start
2025-08-27
Primary completion
2030-09-15
Completion
2030-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Q702 Small molecule — Oral

Indications

CD4+/CD56+ hematodermic neoplasm Erdheim-Chester disease Langerhans cell histiocytosis Waldenstrom macroglobulinemia chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myelomonocytic leukemia follicular lymphoma histiocytic sarcoma interdigitating dendritic cell sarcoma malignant histiocytosis myelodysplastic syndrome myelofibrosis peripheral T-cell lymphoma, not otherwise specified primary central nervous system lymphoma primary cutaneous T-cell non-Hodgkin lymphoma reticulum cell sarcoma sinus histiocytosis with massive lymphadenopathy